February 2, 2021 7:52am
‘til the short positions decline and earnings’ LPS (loss-per-share) release
Pre-open indication: 7 SELLs and 4 BUYs
What I provide is a trusted source of share pricing intelligence that ensures that investors are kept apprised of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!
Dow futures are UP +0.82% (+247 points), S&P futures are UP +0.86% (+32) and NASDAQ futures are UP +0.86% (+113 points)
U.S. stock futures were solidly higher early Tuesday,
European stocks advanced as global markets reflect positive investor sentiment that an economic recovery;
Asia-Pacific stocks rose following an overnight jump begun in the U.S.
Data Docket: the euro zone economy dropped by 0.7% in Q4/2020 as governments stepped up social restrictions, Eurostat revealed on Tuesday, while a preliminary reading points to an annual GDP contraction of 6.8%.
The stock market was coming off its worst week since October after Monday’s large gains.
For color, Pfizer (PFE) releases earnings today … expects to sell about $15 billion in coronavirus vaccine doses this year, the company releasing its Q4 and FY20 earnings. It forecast between $59.4 and $61.4 billion in revenue this year.
Market focus remains on the retail trading frenzy that has taken place over the last couple of weeks in stocks shorted by hedge funds.
Monday’s evening’s recap: “new month, still volatile as sector equities rebound” … https://www.regmedinvestors.com/articles/11748
- The Nasdaq closed UP +332.70 points (+2.55%);
- The IBB closed up +1.28% and XBI closed up +4.41%;
- Sector volume was LOW with 2 of the 22-upside having higher than the 3-month average volume with the increased volume of 2 of 11-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -2.85 points or -8.61% at 30.24;
- Monday’s percentage (%) of the22 -upside were +0.16% (ADVM) to +26.10% (ATHX) while the 11-downside ranges from -0.01% (CRSP) to -9.03% (BLCM);
February: 1 positive close
January: 10 positive, 9 negative closes and 1 holiday, so far
Companies in my headlights – It’s your decision; I provide an idea and context:
Biostage (BSTG) closed up +$0.13 to $1.93 with 1,211 shares traded after Friday’s -$0.06 to $1.80 with 7,338 shares traded after Thursday’s +$0.06 to $1.86 with 15,597 shares traded, Wednesday’s $1.80 with 2,300 shares traded and last Tuesday’s $1.80 with 2,500 shares traded.
- Question#1: Volume of shares traded without any news for months and quarters does NOT correlate; does it reflect desperation of DST Capital or its cohorts that is pumping the share volume for pricing in an attempt to exercise the outstanding warrants?
- Question#2: WHO is responsible for the dying trajectory of the approved IND’s initiation of a clinical trial; isn’t it - William (Bill) Fodor – CSO (chief scientific officer)? Is it not CSO Fodor’s responsibility to advance the science – are there problems you haven’t told the public shareholders and WHERE is the BLAME due?
- Question#3: WHY is TRANSPARENCY such a major issue for BSTG’s lack of communication to public shareholders?
- Question#4: WHEN does the clinical trial initiate or is there yet, another payment issue with a CRO as the last one (BBA) refused to file the IND unless paid?
SELL into Strength:
Athersys (ATHX) closed up +$0.50 to $2.44 with a positive +$0.04 or 1.64% aftermarket indication
Editas Medicine (EDIT) closed up +$1.54 to $62.89 after Friday’s $61.35, Thursday’s $61.13, Wednesday’s $60.50 after last Tuesday’s $60.58 with a positive +$0.34 or +0.54% aftermarket indication;
Homology Medicine (FIXX) closed up +$0.30 to $12.45 after Friday’s -$0.29 to $12.15, Thursday’s -$0.03 to $12.44, Wednesday’s -$0.57 to $12.47 and last Tuesday’s $13.04 with a negative -$0.24 or -1.93% aftermarket indication;
Vericel (VCEL) closed up +$3.10 to $44.37 after Friday’s $41.27, Thursday’s $41.10, Wednesday’s $40.15 and last Tuesday’s $40.85 with a positive +$0.61 or +1.37% aftermarket indication. I might be wrong but, I SMELL a public offering (outstanding shares of 45.34 and a float of 41.04 M shares, a 52-week low of $6.78 and a high of $44.84);
Caladrius Biosciences (CLBS) closed down -$0.04 to $2.08 after a $2.00 offering of a 12.5 M share private placement with 6.25 M warrants with a negative -$0.03 or -1.44% aftermarket indication;
SELL from BUY:
bluebird bio (BLUE) closed up +$1.19 to $45.74 after Friday’s -$0.45 to $44.55, Thursday’s -$1.77 to $45.00, Wednesday’s $46.77 after last Tuesday’s $46.07 with a negative -$0.14 or -0.31% aftermarket indication;
CRISPR Therapeutics (CRSP) closed down -$0.02 to $165.68 after Friday’s $165.68, Thursday’s $167.42, Wednesday’s $163.95 and last Tuesday’s $169.53 with a positive +$2.10 or +1.27% aftermarket indication;
Global Blood Therapeutics (GBT) closed down -$0.63 to $49.49 after Friday’s +$1.78 to $50.12, Thursday’s -$2.46 to $48.34, Wednesday’s +$3.31 to $50.80 and last Tuesday’s $47.49, with a positive +$0.11 or +0.22% aftermarket indication;
Ionis Pharmaceuticals (IONS) closed down -$1.10 to $58.97 after Friday’s -$0.62 to $60.07, Thursday’s $60.69, Wednesday’s $59.19, Tuesday’s $62.52 and last Monday’s $63.78 with a positive +$1.03 or +1.75% aftermarket indication;
Pluristem (PSTI) closed up +$0.47 to $7.46 after Friday’s -$0.12 to $6.99, Thursday’s $7.11, Wednesday’s $7.08, Tuesday’s $7.30 and last Monday’s $7.45 with a positive +$0.35 or +5.08% aftermarket indication;
The BOTTOM LINE: As I have stated, “There is STILL a short-term tone in the sector – “our’ universe of RegMed, stem, cell and gene therapy equities.”
Again, “forewarned … earnings LPS (los-per-share) season is coming quickly – my advice, trim and skim!”
Started early, even got the found in closet - snow pants out – beautiful but heavy snow as a little shoveling will be the exercise of the day (I also got plowed-out).
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.